This inventor holds 6 USPTO granted patents and 2 published patent applications and 3 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation. Active years: 2001-2019.
Company Filing History:
Years Active: 2001-2019
Title: David C Wylie: Innovator in Pegylated Interleukin-10
Introduction
David C Wylie is a notable inventor based in Cranford, NJ (US). He has made significant contributions to the field of biochemistry, particularly in the development of pegylated interleukin-10. With a total of 6 patents to his name, Wylie has established himself as a key figure in innovative therapeutic solutions.
Latest Patents
Wylie's latest patents focus on pegylated interleukin-10, specifically the conjugation of interleukin-10 (IL-10) via a linker to one or more polyethylene glycol (PEG) molecules. This process occurs at a single amino acid residue of the IL-10. The method he developed produces a stable mono-pegylated IL-10 that retains its biological activity. Notably, the pegylation is selective for the N-terminus on one subunit of IL-10, resulting in minimal formation of monomeric IL-10. Furthermore, this method yields a substantially homogenous population of mono-PEG-IL-10.
Career Highlights
Throughout his career, David C Wylie has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme Corp. and Schering Corporation. His work has significantly impacted the development of therapeutic agents, particularly in the realm of immunology.
Collaborations
Wylie has collaborated with esteemed colleagues such as Seoju Lee and Susan V Cannon-Carlson. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
David C Wylie is a distinguished inventor whose work in pegylated interleukin-10 has paved the way for innovative therapeutic approaches. His contributions to the field continue to influence the development of effective treatments in immunology.